- Cardinal Health‘s 4Q adjusted EPS reached $1.84, surpassing last year’s $1.55 and exceeding estimates of $1.73.
- Adjusted operating income stood at $605 million, marking an 8% year-over-year increase and beating the estimate of $602 million.
- Revenue surged to $59.87 billion, a 12% growth from the previous year, surpassing the $58.54 billion estimate.
- Global Medical Products and Distribution revenue amounted to $3.11 billion.
- Cash from operating activities reached $2.08 billion, significantly higher than last year’s $858 million and above the estimate of $952.6 million.
- For fiscal year 2025, the company adjusted its non-GAAP diluted EPS outlook to a range of $7.55 to $7.70, higher than the previous minimum expectation of $7.50.
- Cardinal Health also increased its share repurchase goals for fiscal year 2025 by $250 million, bringing the total to $750 million.
- The company reported robust cash flow, continued profit growth in its Pharmaceutical and Specialty Solutions segment, and significant improvements driven by its GMPD Improvement Plan.
- Analyst ratings: 9 buys, 9 holds, 1 sell.
Cardinal Health on Smartkarma
Analyst coverage of Cardinal Health on Smartkarma showcases a positive outlook from Baptista Research. In their report titled “Cardinal Health: Deep-Rooted Market Relationships & Competitive Edge! – Major Drivers,” the analysts highlight the company’s strong Q3 FY2024 financial performance. Cardinal Health demonstrated broad-based growth, attributing its success to focusing on four strategic priorities. The pharmaceutical and specialty solutions business experienced notable growth, supported by ongoing stability in pharmaceutical demand. Baptista Research‘s bullish sentiment suggests confidence in Cardinal Health‘s future prospects.
A look at Cardinal Health Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Cardinal Health, Inc. is positioned for a stable long-term outlook, according to Smartkarma Smart Scores. With a strong resilience score of 5, the company demonstrates robustness and adaptability in the face of challenges. This reflects positively on its ability to weather uncertainties and maintain performance over time. Additionally, Cardinal Health scores a respectable 3 on both the dividend and growth factors, indicating a balance between rewarding investors through dividends and potential for growth in the future.
However, the company lags slightly in momentum with a score of 2, suggesting a slower pace in price movement compared to its peers. While the value score is at 0, this may indicate that Cardinal Health is currently not undervalued based on certain metrics. Overall, Cardinal Health, Inc. stands out for its resilience and steady performance, making it a noteworthy player in the healthcare industry providing a wide range of essential products and services to healthcare providers and manufacturers.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
